

The Expression and Clinical Significance of Programmed Cell Death Receptor 1 and Its Ligand in Tumor Tissues of Patients with Extranodal Nasal NK/T Cell Lymphoma

Yu Feng

West China Hospital of Sichuan University

Xia Feng

The Public Health Clinical Center of Chengdu

Caixia Jing

West China Hospital of Sichuan University

Xinmei Yu

West China Hospital of Sichuan University

Caigang Xu (✉ xucaigang@wchscu.cn)

West China Hospital of Sichuan University

Research Article

Keywords: Extranodal natural killer/T-cell lymphoma, programmed cell death receptor 1, programmed cell death ligand 1, disease staging, treatment response assessment.

Posted Date: June 23rd, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-601816/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Scientific Reports on January 7th, 2022. See the published version at <https://doi.org/10.1038/s41598-021-02515-5>.

Abstract

Appropriate biomarkers may help distinguish the biological behavior of different types of lymphoma and their response to traditional chemotherapy. Extranodal natural killer/T-cell lymphoma (ENKTL) and diffuse large B-cell lymphoma (DLBCL) belong to different subtypes of non-Hodgkin's lymphoma, the biological behavior and prognosis of them are very different, programmed cell death receptor 1 (PD-1) and its ligand (PD-L1) have been investigated in these two types of diseases. However, few studies addressed the difference of PD-1/PD-L1 levels between ENKTL and DLBCL, in order to find out the difference and related clinical application value, the clinical data and tumor tissue paraffin sections of 24 newly diagnosed ENKTL patients and 42 newly diagnosed diffuse large B-cell lymphoma (DLBCL) were collected. PD-1/PD-L1 levels in tumor tissues were detected by immunohistochemical staining. The relationship between the PD-1/PD-L1 levels and clinical data of patients with ENKTL patients was analyzed. Both patient groups showed PD-1 level in tumor tissue of ENKTL patients was significantly lower than that of DLBCL patients ($P < 0.05$), while the PD-L1 level in tumor tissues of ENKTL patients was not different from DLBCL ($P < 0.05$). In addition, the ENKTL patients with B symptoms, elevated lactate dehydrogenase (LDH) levels and decreased hemoglobin (HGB) concentrations had lower level of PD-1 in tumor tissue. PD-L1 level in tumor tissues, the LDH level, Epstein-Barr genome (EBV-DNA) copy and Ki-67 index may affect the efficacy of ENKTL patients ($P < 0.05$), but they were not independent factors. PD-L1 levels in tumor tissues has clinical significance in ENKTL patients, which suggested that the PD-1/PD-L1 signal pathway may be involved in the immune escape of ENKTL and play different roles in different lymphoma subtypes.

Introduction

Extranodal NK/T-cell lymphoma, nasal type (ENKTL) is an aggressive non-Hodgkin lymphoma which originates from T cell or NK-like cell, it often involve the nasal cavity, face and upper respiratory tract. Compared to diffuse large B-cell lymphoma (DLBCL), this disease is characterized by more difficult diagnosis, higher malignant, rapider progress, and easier to be resistant to traditional chemotherapy. Therefore, there is currently no standard treatment plan for ENKTL^[1]. The above characteristics are probably related to tumor cells evading the immune response of the body, the signaling pathway involving programmed cell death receptor 1 (PD-1) is likely one mechanisms of immune evasion^[2].

Existing studies have shown that PD-1 is mainly expressed on CD4 + or CD8 + T cell membranes, and it has two types of ligands, which are PD-L1 and PD-L2. PD-L1 is the main ligand of PD-1 in the human body, PD-L1 is expressed in not only immune cells such as activated lymphocytes, NK cells and macrophages, but also tissue cells such as lung and vascular endothelium^[2]. What is more, it is expressed at high levels in tumor cells, such as melanoma^[3], gastric cancer^[4], kidney cancer^[5], high levels of PD-L1 expressed on tumor cells can inhibit the proliferation and activation of lymphocytes by interacting with PD-1 on lymphocytes to achieve the immune escape of tumor cells^[2]. Recent studies have shown that PD-L1 level in nasal biopsy tissues of ENKTL patients is much higher than that of

rhinitis patients^[6]. Based on the above background, we used a retrospective case-control study to analyze the differences in PD-1/PD-L1 levels in tumor tissues of between ENKTL and DLBCL patients.

Therefore we examined PD-1/PD-L1 in tumor tissues of ENKTL and DLBCL patients. Our results show that PD-1/PD-L1 level in tumor tissues of ENKTL patients are useful for ENKTL staging and prediction of treatment response. The same results were not obtained for patients with DLBCL, another type of lymphoma, suggesting that the biomarker may show some specificity for ENKTL.

Materials And Methods

Study population and treatment

This retrospective study included 24 cases of ENKTL (18 males, median age 49.5 years) diagnosed in West China Hospital of Sichuan University from December 2017 to December 2018 and 42 cases of DLBCL patients, and pathological paraffin sections of all 66 patients have been obtained from the Department of Pathology, West China Hospital, Sichuan University. The diagnostic criteria are based on the 2008 WHO classification criteria for hematopoietic and lymphoid tissue tumors^[7]. The efficacy evaluation after two courses of chemotherapy follows the "Evaluation Criteria for the Efficacy of Malignant Lymphoma", including complete remission (CR), partial remission (PR), stable disease (SD) and disease progression (PD)^[8]. We have signed an informed consent form with all research subjects, and have been approved by the Ethics Committee of West China Hospital of Sichuan University. All methods are performed in accordance with the relevant guidelines and regulations.

Immunohistochemical staining (IHC) for PD-1/PD-L1

Paraffin-embedded sections (3um) were used for immunohistochemical staining (IHC). After being dewaxed and hydrated, they were incubated with a 1:75 dilution of PD-L1 antibody [28 – 8] (Abcam, Cambridge, UK) / PD-1 antibody (Zhongshan Jinqiao, Beijing, China). IHC was accomplished by avidin-biotin peroxidase complex detection system. The percentage of PD-1/PD-L1 expression (the number of cells stained with membranes in the total number of tumor cells) was analyzed by Image J software. The percentage > 30% was defined as PD-L1 (+), while the percentage > 5% was considered PD-1 (+)^[9].

Statistical analyses

PD-1/PD-L1 level in tumor tissues are presented as the median and interquartile range [M(IQR)]. The Kruskal-Wallis test was used to analyze the differences between groups, and the Mann-Whitney U test and Spearman rank correlation analysis were used to analyze the relationship between PD-1/PD-L1 level in tumor and the clinical data of patients. Fish test and Logistic regression were used to conduct univariate and multivariate analysis of predictors of treatment response in ENKTL patients. We set P value < 0.05 as the significant difference.

Results

Baseline clinical characteristics of patients

Baseline clinical characteristics of 24 patients with ENKTL and 42 ones with DLBCL are summarized in Table 1. In the ENKTL group, 7 (29%) was in stage III-IV, and 8 (33%) had LDH > 250 U/L. 23 (88%) patients accepted anthracycline-containing chemotherapy regimens. All patients received at least two cycles of chemotherapy before radiotherapy. After two courses of chemotherapy, 8 patients (33%) achieved CR.

Table 1
Baseline and clinical characteristics of 66 patients

Characteristics	ENKTL patients (n = 24)	DLBCL patients (n = 42)
Age, year		
> 60	5 (21)	18(43)
≤ 60	19 (79)	24(57)
Sex		
male	18 (75)	19(45)
female	6 (25)	23(55)
Ann Arbor Stage		
I-II	17 (71)	29(69)
III-IV	7 (29)	13(31)
Bulky mass		
Yes	1 (4)	11(26)
No	23 (96)	31(74)
B symptoms		
Yes	14 (58)	15(36)
No	10 (42)	27(64)
Extranodal sites		
> 1	20 (83)	8(19)
≤ 1	4 (17)	34(81)
ECOG PS		
≥ 1	4 (17)	12(29)
< 1	20 (83)	32(71)
Bone marrow involvement		
Yes	1 (4)	2(5)
No	23 (96)	40(95)

Values are n (%).

DLBCL, diffuse large B-cell lymphoma; ECOG PS, Eastern Cooperative Oncology Group performance score; ENKTL, extranodal natural killer/T-cell lymphoma; PINK-E, prognostic index of extranodal natural killer/T-cell lymphoma; IPI, international prognostic index; "-", data not collected.

Characteristics	ENKTL patients (n = 24)	DLBCL patients (n = 42)
Lactate dehydrogenase (U/L)		
> 250	8 (33)	17(40)
≤ 250	16 (67)	25(60)
EBER(+)		
Yes	24(100)	-
No	0(0)	-
PINK-E and IPI		
Low (0–2)	16 (67)	33(79)
High (≥ 3)	8 (33)	9(21)
Chemotherapy		
Anthracycline	21(88)	-
Non-anthracycline	3 (12)	-
Response after two treatment courses		
Complete remission	8 (33)	-
Other	16 (67)	-
Values are n (%).		
DLBCL, diffuse large B-cell lymphoma; ECOG PS, Eastern Cooperative Oncology Group performance score; ENKTL, extranodal natural killer/T-cell lymphoma; PINK-E, prognostic index of extranodal natural killer/T-cell lymphoma; IPI, international prognostic index; “-”, data not collected.		

PD-1 and PD-L1 levels in tumor tissues and relationships with clinical variables

The distribution and expression of PD-1/PD-L1 in tumor tissues were investigated by immunohistochemical staining. Membranes of positive cells in tumor tissues from ENKTL and DLBCL patients were stained brown (Fig. 1). PD-L1 (+) was defined as positive cells proportion > 30% and PD-1 (+) as > 5% [9]. In 24 ENKTL patients, 19 (79%) were PD-L1 (+) and 9 (38%) were PD-1(+) (Fig. 2A). In 42 DLBCL patients, 25 (60%) were PD-L1 (+) and 29 (69%) were PD-1 (+) (Fig. 2B). PD-1 level in tumor tissues in ENKTL patients [3.50(0.00-9.75)] was significantly lower than in DLBCL patients [21.00(1.75-44.00), $P = 0.0021$] (Fig. 2C), while PD-L1 level was not statistically different between ENKTL [49.50(35.25-80.00)] and DLBCL [50.50(2.50–77.00)] groups (Fig. 2D). In ENKTL patients, PD-1 level in tumor tissues were significantly lower with B symptoms, higher levels of LDH ($P < 0.05$, Fig. 3A), and lower hemoglobin level (Spearman $r = 0.6131$, $P = 0.0014$, Fig. 3B).

Association of PD-1 or PD-L1 biomarkers with treatment response

As shown in Table 2, Univariate analysis showed that ENKTL patients with higher levels of PD-L1 in tumor tissues ($P = 0.0218$) were more difficult to achieve CR, as were patients with high levels of LDH ($P = 0.0222$), Ki-67 index ($P = 0.0304$) and EBV-DNA copies ($P = 0.0087$). In multivariate analysis, however, no one varied significantly with treatment response.

Table 2

Univariate and multivariate analyses to identify predictors of treatment response among ENKTL patients

Variable	Univariate analysis		P	Multivariate analysis		P
	Complete remission (n = 8)	Other treatment response (n = 16)		OR	95%CI	
Age > 60(years)			0.2885			
Yes	3(38)	2(14)				
No	5(62)	14(86)				
Sex			0.3618			
Male	5(62)	13(81)				
Female	3(38)	3(19)				
Ann Arbor stage			0.3521			
I-II	7(88)	10(63)				
III-IV	1(12)	6(37)				
Bulky mass			1.000			
Yes	0(0)	1(6)				
No	8(100)	15(94)				
B symptoms			0.6734			
Yes	4(50)	10(63)				
No	4(50)	6(37)				
Extranodal sites			0.5784			
> 1	6(75)	14(86)				
≤ 1	2(25)	2(14)				
ECOG PS			0.5784			
≥ 1	2(25)	2(14)				
< 1	6(75)	14(86)				

Values are n (%) or median (interquartile range)

ENKTL, extranodal natural killer/T-cell lymphoma; ECOG PS, Eastern Cooperative Oncology Group performance score; PINK-E, Prognostic Index of extranodal natural killer/T-cell lymphoma; OR, odd ratio; 95%CI, 95%

Variable	Univariate analysis		P	Multivariate analysis		P
	Complete remission (n = 8)	Other treatment response (n = 16)		OR	95%CI	
Bone marrow involvement			0.3333			
Yes	1(12)	0(0)				
No	7(88)	16(100)				
Lactate dehydrogenase > 250U/L			0.0222	0.972	0.932 ~ 1.014	0.187
Yes	0(0)	8(50)				
No	8(100)	8(50)				
PINK-E			0.1893			
Low (0-2)	7(88)	9(56)				
High (≥ 3)	1(12)	7(44)				
Chemotherapy			0.2490			
Anthracycline	2(25)	1(6)				
Non-anthracycline	6(75)	15(94)				
Hemoglobin, g/L	135.5(114 ~ 142.5)	127.0(114 ~ 144.5)	0.6205			
Platelet count, 10 ⁹ /L	201.0(164.5 ~ 235.8)	206.0(172.8 ~ 296.5)	0.4435			
Lymphocyte count, 10 ⁹ /L	1.435(1.208 ~ 1.848)	1.290(0.805 ~ 1.580)	0.4254			
Lymphocyte percentage, %	28.60% (18.90%~31.05%)	22.05% (13.65%~26.30%)	0.1199			
Copies of Epstein-Barr virus genome	32.70(10.30 ~ 317.3)	1420(155.3 ~ 35025)	0.0087	0.994	0.840 ~ 1.022	0.171

Values are n (%) or median (interquartile range)

ENKTL, extranodal natural killer/T-cell lymphoma; ECOG PS, Eastern Cooperative Oncology Group performance score; PINK-E, Prognostic Index of extranodal natural killer/T-cell lymphoma; OR, odd ratio; 95%CI, 95%

Variable	Univariate analysis		P	Multivariate analysis		P
	Complete remission (n = 8)	Other treatment response (n = 16)		OR	95%CI	
Ki-67, %	47.50% (41.25%~55.00%)	67.50% (46.25%~73.75%)	0.0304	0.871	0.758 ~ 1.002	0.054
PD-1 level in tumor tissues, %	6.00% (2.50%~10.50%)	0.00% (0.00%~9.75%)	0.2256			
PD-L1 level in tumor tissues, %	35.50% (10.00%~59.00%)	64.00% (41.50%~83.25%)	0.0218	0.926	0.840 ~ 1.022	0.126
Values are n (%) or median (interquartile range)						
ENKTL, extranodal natural killer/T-cell lymphoma; ECOG PS, Eastern Cooperative Oncology Group performance score; PINK-E, Prognostic Index of extranodal natural killer/T-cell lymphoma; OR, odd ratio; 95%CI, 95%						

Discussion

Studies have found that in patients with follicular lymphoma, PD-1 is mainly expressed on CD4 + T lymphocytes in lymph node follicles [12]. Roncador G, García Verdes-Montenegro JF found that PD-1 is abnormally highly expressed in tissues of patients with angioimmunoblastic lymphoma (AITL) [14], and other studies have reported the low level of PD-1 in tumor tissues of ENKTL patients [15]. However, this study found that PD-1 level in tumor tissues of ENKTL patients was significantly lower than that of DLBCL patients, and that PD-1 level in tumor tissues of ENKTL patients with B symptoms, increased LDH levels, and decreased hemoglobin concentration was lower. We believe that the low level of PD-1(+) infiltrating lymphocytes constitutes the immunosuppressive effect of lymphoma cells in tumor microenvironment and promotes tumor immune escape, from this perspective, the lower PD-1 level in ENKTL tumor tissue may be one of the possible reasons why ENKTL progresses faster than DLBCL.

In addition, Chen BJ, Chapuy B and other scholars have found that PD-L1 is expressed in HL, DLBCL, ENKTL and other lymphoma tissues, but no expression has been detected in Burkitt lymphoma [13], similar to this, this study is also found that PD-L1 is highly expressed in tumor tissues of ENKTL and DLBCL patients, it is suggested that the increased expression of PD-L1 is one of the possible reasons for the defect of cellular immune function in patients.

The efficacy-related analysis in ENKTL patients found that the LDH level, EBV-DNA copy number, Ki-67 index and PD-L1 level in tumor tissues will affect the efficacy of ENKTL patients, but are not independent

factors, this suggests that the PD-1/PD-L1 signaling pathway may be involved in the disease progression of ENKTL patients, and is closely related to the patient's response to traditional chemotherapy.

In summary, the results of this study showed that the expression of PD-1/PD-L1 in the tumor tissues of patients is different in ENKTL and DLBCL patients, suggesting that the PD-1/PD-L1 signaling pathway has different roles in different lymphoma subtypes.

Declarations

Ethics approval and consent to participate

This study was approved by the Ethics Committee of West China Hospital of Sichuan University. Participants provided written consent for their anonymized clinical data to be used and published for research purposes.

Data availability

The datasets generated and analyzed in the current study are available from the corresponding author on reasonable request.

Conflict of interest statement

The authors declare no conflicts of interest.

Funding

This research was supported by a grant to C.X. from the Sichuan Science and Technology Program (2008FG0005).

Acknowledgements

C.X. initiated the project and designed the research. Y.F. and X.F. performed most experiments, analyzed the data, and drafted the manuscript. X.F. assisted in collecting clinical specimens. C.J., X.C., and X.Y. performed some experiments and provided critical suggestions.

References

1. Kwong YL, Chan AC, Liang R, et al. CD56+ NK lymphomas: clinicopathological features and prognosis. *Br J Haematol* 1997, 97(4), 821-829.
2. Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. *Annu Rev Immunol* 2008, 26, 677-704.
3. Chen G, Huang AC, Zhang W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. *Nature* 2018, 560(7718), 382-386.

4. Wu C, Zhu Y, Jiang J, et al. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. *Acta Histochem* 2006, 108(1), 19-24.
5. Thompson RH, Kuntz SM, Leibovich BC, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. *Cancer Res* 2006, 66(7), 3381-3385.
6. Han L, Liu F, Li R, Li Z, Chen X, Zhou Z, Zhang X, Hu T, Zhang Y, Young K, Sun S, Wen J, Zhang M. Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma. *Oncol Lett.* 2014 Oct;8(4):1461-1469.
7. Sabattini E, Bacci F, Sagrmoso C, et al. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. *Pathologica* 2010, 102(3), 83-87.
8. Cheson BD, Pfistner B, Juweid ME, et al. International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. *J Clin Oncol.* 2007, 25(5):579-86.
9. Kiyasu J, Miyoshi H, Hirata A, et al. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. *Blood.* 2015, 126(19):2193-201.
10. Yang QP, Zhang WY, Yu JB, et al. Subtype distribution of lymphomas in Southwest China: analysis of 6,382 cases using WHO classification in a single institution. *Diagn Pathol.* 2011; 6:77.
11. Nagato T, Ohkuri T3, Ohara K, et al. Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy, *Cancer Immunol Immunother.* 2017, 66(7):877-890.
12. Yang ZZ, Grote DM, Ziesmer SC, et al. PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival. *Blood Cancer J.* 2015, 5:e281.
13. Chen B J, Chapuy B, Ouyang J, et al. PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies. *Clinical Cancer Research.* 2013,19(13):3462-3473.
14. Roncador G, García Verdes-Montenegro JF, et al. Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma. *Haematologica.* 2007, 92(8):1059-66.
15. Jo JC, Kim M, Choi Y, et al. Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type. *Ann Hematol.* 2017, 96(1):25-31.

Figures




Figure 1

Immunohistochemical staining of PD-1 (a1-3, b1-3) and PD-L1 (c1-3, d1-3) under the microscope of 100, 200, 400 times.




Figure 2

Details and correlation analysis of PD-1/PD-L1 expression in tumor tissues of ENKTL (A) and DLBCL (B) patients. No correlation was found between PD-1 and PD-L1 level from tumor tissues of ENKTL and DLBCL patients. Scatter plot of PD-1 (C) and PD-L1 (D) expression showed that PD-1 level in tumor tissues from ENKTL patients was lower than DLBCL. ** $P<0.01$.




Figure 3

(A-B) In ENKTL patients, PD-1 level in tumor tissues varied with (A) B symptoms, (A) lactate dehydrogenase(LDH) concentration, (B)hemoglobin. *P<0.05.